Mobile

The trial is designed to determine the safety and efficacy of ABP 501 compared with Adalimumab in subjects with moderate to severe rheumatoid arthritis

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-000525-31

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective for this study is to assess the efficacy of ABP 501 compared with adalimumab.

Critère d'inclusion

  • Moderate to Severe Rheumatoid Arthritis

Liens